Patients who have participated in any scientific investigation using an investigational drug inside of 1 month prior to screening or inside of five fifty percent-life with the investigational treatment method whichever is for a longer time. The anti-PD1 antibody camrelizumab has long been utilized with another epigenetic inhibitor decitabine in https://hilaryr777bny0.kylieblog.com/profile